Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy

Thrombosis Research

Volumn 124, Issue 6, 2009, Pages 711-713

  Di Minno, Matteo Nicola Dario ^a   Palmieri, Vittorio ^a   Lombardi, Gaetano ^a   Pezzullo, Salvatore ^a   Cirillo, Ferdinando ^a   Di Somma, Carolina ^a   Valle, Domenico ^b   Di Minno, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Eli Lilly and Co   (Italy)

Author keywords

GH deficient adults; IGF 1; insulin; PAI 1; r HGH treatment; t PA

Indexed keywords

BIOLOGICAL MARKER; HUMAN GROWTH HORMONE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; FEMALE; FIBRINOLYSIS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 70449522171     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.018     Document Type: Article

References (28)

1. Attanasio A.F., Bates P.C., Ho K.K., Webb S.M., Ross R.J., Strasburger C.J., et al. Hypopituitary Control and Complications Study International Advisory Board. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87 (2002) 1600-1606
2. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47 (1998) 1643-1649
3. Colao A., Di Somma C., Rota F., Pivonello R., Savanelli M.C., Spiezia S., et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90 (2005) 2056-2062
4. Di Minno G., Grandone E., and Margaglione M. Clinical relevance of polymorphic markers of arterial thrombosis. Thromb Haemostasis 78 (1997) 462-466
5. Elhadd T.A., Abdu T.A., Oxtoby J., Kennedy G., McLaren M., Neary R., et al. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab 86 (2001) 4223-4232
6. Gómez J.M., Sahún M., Vila R., Domènech P., Catalina P., Soler J., et al. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) 64 (2006) 632-639
7. Hamsten A., De Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
8. Hou B., Eren M., Painter C.A., Covington J.W., Dixon J.D., Schoenhard J.A., et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 279 (2004) 18127-18136
9. Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Haemostasis 11 (2001) 183-193
10. Johansson J.O., Landin K., Johannsson G., Tengborn L., and Bengtsson B.A. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemostasis 76 (1996) 422-428
11. Jansonn J.H., Olofsson B.O., and Nilsson T.K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary heart disease. Circulation 88 (1993) 2030-2034
12. Johansson J.O., Landin K., Tengborn L., Rosén T., and Bengtsson B.A. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 14 (1994) 434-437
13. Kehely A., Bates P.C., Frewer P., Birkett M., Blum W.F., Mamessier P., et al. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 87 (2002) 1974-1979
14. Kralisch S., Klein J., Lossner U., Blu{double acute}her M., Paschke R., Stumvoll M., et al. Plasminogen activator inhibitor-1 expression and secretion are stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Mol Cell Endocrinol 253 (2006) 56-62
15. Kvasnicka J., Marek J., Kvasnicka T., Weiss V., Marková M., Stěpán J., et al. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf) 52 (2000) 543-548
16. Margaglione M., Cappucci G., d'Addedda M., Colaizzo D., Giuliani N., Vecchione G., et al. PAI plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 18 (1998) 562-567
17. Margaglione M., Grandone E., Vecchione G., Cappucci G., Giuliani N., Colaizzo D., et al. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward. Relation to polymorphism of PAI-1 and angiotensin-converting enzime (ACE) genes. Arterioscler Thromb Vasc Biol 17 (1997) 2082-2087
18. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., and Miller G.J. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342 (1993) 1076-1079
19. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., and Vaughan D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87 (1993) 1969-1973
20. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., and Hennekens C.H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341 (1993) 1165-1168
21. Ridker P.M., Hennekens C.H., Stampfer M.J., Manson J., and Vaughan D.E. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 343 (1994) 940-943
22. Rosén T., and Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336 (1990) 285-288
23. Sartorio A., Cattaneo M., Bucciarelli P., Bottasso B., Porretti S., Epaminonda P., et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 108 (2000) 486-492
24. Smith J.C., Evans L.M., Wilkinson I., Goodfellow J., Cockcroft J.R., Scanlon M.F., et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 56 (2002) 493-501
25. Tomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357 9254 (2001) 425-431
26. Vaughan D.E., Lazos S.A., and Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the rennin-angiotensin system and thrombosis. J Clin Investig 95 (1995) 995-1001
27. Vaughan D.E. Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. Circulation 108 (2003) 376-377
28. Weaver J.U., Monson J.P., Noonan K., John W.G., Edwards A., Evans K.A., et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80 (1995) 153-159